PHILADELPHIA (WPVI) -- Every October, the Philadelphia Film Festival transforms the city into a global stage, curating the best films from around the world. This year, there are more than 100 feature ...
The movie theater at 1412 Chestnut St. has been closed for the past four months as crews gutted the lobby and upgraded the historic space, currently the home base of the Philadelphia Film Society. Now ...
Pieter Sonneveld, MD, PhD, chair of the Erasmus MC Cancer Institute, discussed the findings of a study modeling long-term progression-free survival (PFS) in patients with multiple myeloma (MM) treated ...
New results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study showed that a combination of pembrolizumab and concurrent chemoradiotherapy (CCRT) continues to ...
On January 17, 2025, PFS Investments Inc., a broker-dealer affiliated with Primerica (“Primerica”), filed a notice of data breach with the Attorney General of Massachusetts after discovering that ...
Please provide your email address to receive an email when new articles are posted on . The addition of palbociclib to anti-HER2 and endocrine therapy extended PFS by more than a year. The regimen ...
Following a pair of similar deals in January and June, Coherus BioSciences has netted itself a hefty chunk of change for the last biosimilar in its portfolio, in turn freeing up the company to go ...
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...
Brian Cheng - JPMorgan Chase & Co. Douglas Tsao - H.C. Wainwright & Co. Good day, and thank you for standing by. Welcome to the Coherus BioSciences’ Second Quarter 2024 Earnings Conference Call. At ...
Patients with age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion can use faricimab-svoa as a prefilled syringe (PFS). Faricimab-svoa (Vabysmo) ...
REDWOOD CITY, Calif., June 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced it agreed to divest YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback